口服抗病毒药对高龄住院新冠患者死亡风险的效果:目标试验模拟研究
结果显示两药均中度降低死亡风险,且效果不受既往疫苗接种状态影响。
要点
- 莫诺拉韦与奈玛特韦-利托那韦均中度降低高龄住院新冠患者死亡风险
- 两药效果不受患者既往疫苗接种状态影响
- 28天死亡风险差值绝对值约1–2个百分点,置信区间接近或跨零
核心结论
- 莫诺拉韦和奈玛特韦-利托那韦对≥80岁住院新冠患者具有中度降低死亡风险的效果。
- 两药的效果不受患者既往疫苗接种状态影响。
研究设计与样本
- 基于香港全境公共医疗数据库开展的目标试验模拟研究。
- 主要结局为全因死亡,采用克隆-删失-加权方法减少不死时间偏倚和混杂偏倚。
- 通过稳定逆概率加权调整混杂后,用合并逻辑回归估计死亡比值比。
主要发现
- 莫诺拉韦组全因死亡HR为0.895(95%CI 0.826–0.970)。
- 奈玛特韦-利托那韦组全因死亡HR为0.804(95%CI 0.678–0.955)。
- 莫诺拉韦组28天死亡风险差值为-1.09%(95%CI -2.29–0.11)。
- 奈玛特韦-利托那韦组28天死亡风险差值为-1.71%(95%CI -3.30–-0.16)。
- 口服抗病毒治疗与疫苗接种状态之间未观察到显著交互作用。
临床怎么用
- 对≥80岁住院新冠患者,可考虑使用莫诺拉韦或奈玛特韦-利托那韦以中度降低死亡风险。
- 决策时不应因患者已接种疫苗而排除口服抗病毒治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molnupiravir and nirmatrelvir-ritonavir are orally administered pharmacotherapies for mild to moderate COVID-19. However, the effectiveness of these drugs among very old (≥80 years), hospitalised patients remains unclear, limiting the risk-benefit assessment of these antivirals in this specific group. This study investigates the effectiveness of these antivirals in reducing mortality among this group of hospitalised patients with COVID-19. METHODS: Using a territory-wide public healthcare database in Hong Kong, a target trial emulation study was conducted with data from 13 642 eligible participants for the molnupiravir trial and 9553 for the nirmatrelvir-ritonavir trial. The primary outcome was all-cause mortality. Immortal time and confounding bias was minimised using cloning-censoring-weighting approach. Mortality odds ratios were estimated by pooled logistic regression after adjusting confounding biases by stabilised inverse probability weights. RESULTS: Both molnupiravir (HR: 0.895, 95% CI: 0.826-0.970) and nirmatrelvir-ritonavir (HR: 0.804, 95% CI: 0.678-0.955) demonstrated moderate mortality risk reduction among oldest-old hospitalised patients. No significant interaction was observed between oral antiviral treatment and vaccination status. The 28-day risk of mortality was lower in initiators than non-initiators for both molnupiravir (risk difference: -1.09%, 95% CI: -2.29, 0.11) and nirmatrelvir-ritonavir (risk difference: -1.71%, 95% CI: -3.30, -0.16) trials. The effectiveness of these medications was observed regardless of the patients' prior vaccination status. CONCLUSIONS: Molnupiravir and nirmatrelvir-ritonavir are moderately effective in reducing mortality risk among hospitalised oldest-old patients with COVID-19, regardless of their vaccination status.
引用
- Lai FTT, Wang B, Wei C, et al. Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study. Age Ageing. 2024. PMID: 39141078. doi:10.1093/ageing/afae180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。